THC Reduced Amphetamine Hyperactivity but Prolonged Stereotyped Movements in Rats

A 1977 rat study found that THC weakened some amphetamine effects while strengthening or prolonging others. Reduced general activity therefore did not mean the combination reduced every stimulant-related behavioral effect.

Activity and stereotypy were different outcomes

THC dose-dependently reduced amphetamine-stimulated movement and opposed an amphetamine-related temperature rise. At higher amphetamine conditions, however, stereotyped movements lasted longer with THC. Those repetitive behaviors should not be merged with an overall activity count.

Other combination effects also persisted

Both compounds reduced food and water intake and body-weight gain, with additive effects in combination. Brainstem dopamine content increased more under the combination than under either reported individual condition. Tissue content is not a direct measure of dopamine release or proof of a particular subjective experience.

Repeated THC did not remove amphetamine effects

Tolerance developed to the tested THC effects, but the study did not find cross-tolerance to amphetamine's pharmacological and biochemical effects. Thus, adaptation to THC did not establish generalized resistance to a stimulant challenge.

The experiment demonstrates why drug interactions need separate behavioral, physiological and biochemical endpoints. It does not establish THC as a way to counter stimulant effects or make combined use safe. Animal doses and tissue measures cannot provide an individual human impairment or toxicity prediction.

Related: interpreting cannabis tolerance claims.

Research cited

Hattendorf C; Hattendorf M; Coper H; Fernandes M. Interaction between delta(9)-tetrahydrocannabinol and d-amphetamine. Psychopharmacology (1977). doi:10.1007/BF00426776. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Psychiatric CBD Review’s Recommendation Grades Included Both CBD and THC-Containing Nabiximols

A review published in 2020 graded psychiatric evidence from studies of CBD and CBD-containing nabiximols. Its recommendation labels should not be quoted as though every underlying intervention was purified CBD or every study was randomized. The included designs ranged widely The review identified 23 relevant studies spanning case reports, case…

Spread the love

Read Article: A Psychiatric CBD Review’s Recommendation Grades Included Both CBD and THC-Containing Nabiximols

CBD Eye Research: Molecular Targets and Clinical Ocular Treatment Are Different Evidence Levels

A 2021 ocular CBD review brought together in-vitro and in-vivo research, proposed molecular targets and possible therapeutic applications. This evidence maps a development pathway; it does not establish that CBD products are effective eye treatments. The experimental system belongs in the conclusion A cellular result can identify a target or…

Spread the love

Read Article: CBD Eye Research: Molecular Targets and Clinical Ocular Treatment Are Different Evidence Levels

CBD Addiction Research Measures Reinforcement, Motivation and Withdrawal as Different Outcomes

A 2021 review evaluated CBD research on reinforcing, motivational and withdrawal-related drug effects. These outcomes can inform substance-use-disorder research, but an improvement in one cannot establish successful treatment across all of them. The source combined preclinical and clinical reports The review covered alcohol, opioids, cannabinoids, nicotine and psychostimulants. An animal…

Spread the love

Read Article: CBD Addiction Research Measures Reinforcement, Motivation and Withdrawal as Different Outcomes

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us